This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Generex Comments On Results Of Stockholders` Meeting

Stocks in this article: GNBT

WORCESTER, Mass. and TORONTO, April 3, 2013 /PRNewswire/ -- Generex Biotechnology Corporation ( (OTCBB: GNBT) today commented on the results of the meeting of the Company`s stockholders held on March 28, 2013.  On April 1, 2013, the Company filed a Form 8-K Current Report with the United States Securities and Exchange Commission detailing the voting results in respect of each of the proposals put forward at the meeting.  That report is publicly available in the online EDGAR database at

The slate of directors put forward in the Company`s proxy statement in respect of the meeting was elected:  John P. Barratt (Chairman of the Board); Brian T. McGee (Chairman of the Audit Committee of the Board of Directors); Dr. James H. Anderson, MD (Chief Scientific Advisor); Dr. Eric von Hofe, PhD (President of Antigen Express, Inc.); and, Mark A. Fletcher (President & Chief Executive Officer).

The proposals to (a) amend the Company`s Restated Certificate of Incorporation to increase the number of shares of common stock authorized thereunder, and (b) authorize the Board to effect a reverse stock split of the Company`s common stock (up until September 27, 2014), were approved by holders of a majority of the Company`s outstanding stock.  The proposal to amend the Company`s stock plan by increasing the number of shares of common stock available thereunder was also approved by the Company`s stockholders.

"We very much appreciate the support and confidence of our stockholders," Mr. Fletcher commented.  "These adjustments to the Generex capital structure will set the stage for the next phase in the life of Generex.  The approval of an increase in authorized capital permits Generex to continue to access the capital markets for the funding necessary to carry on our work.  The approval of a reverse stock split affords the Board flexibility in managing the Company`s capital structure for the benefit of their fellow stockholders.  The amendment of the stock plan will facilitate the retention and engagement of employees and consultants who will play a vital role in the future successes of Generex and Antigen Express.  These initiatives, as a package, will provide a solid foundation upon which our future successes can be securely built."

1 of 4

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs